secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001680367-23-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports Q4 2022 net loss of $25.4M, discontinues SL-279252 program
--------------------------------------------------------------------------------

- Net loss Q4 2022 $25.4M ($0.60/share) vs net income $7.8M in Q4 2021; full-year net loss $101.9M.
- Cash and investments $161.3M at Dec 31, 2022, down from $268.8M; cash runway into H2 2024.
- Discontinued SL-279252 program after Phase 1 failed to meet 20% response rate threshold.
- Initiated Phase 1B trial of SL-172154 + mirvetuximab soravtansine in ovarian cancer; dosed first patients with azacitidine in AML/HR-MDS.
- Appointed Dr. George Fromm as CSO of ARC platform and Dr. Suresh de Silva as CSO of GADLEN platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000017/0001680367-23-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000017/sttk-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001680367-23-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer